Simcere Pharmaceutical

The pharmaceutical company’s profits have been buffeted by erratic returns on an equity stake in a fellow developer of innovative drugs.

Profit setback for Simcere Pharma in novel drugs quest

The pharmaceutical company’s profits have been buffeted by erratic returns on an equity stake in a fellow developer of innovative drugs Key Takeaways: Simcere Pharmaceutical holds a 9% stake in…
2096.HK

Past the Peak? Covid Drugs Frenzy Cools as Pandemic Eases

Simcere Pharmaceutical and Junshi Biosciences have gained marketing approvals for their Covid oral drugs, but the market reaction has been lukewarmKey Takeaways:The drugs Xiannuoxin and Mindewei have been conditionally approved…

Recent Articles

RELATED ARTICLES

  1. Simcere Pharmaceutical Group Ltd. said on Thursday it expects to report its revenue grew between 24% and 26.3% to between 3.35 billion yuan ($468 million) and 3.41 billion yuan in the first half of 2023.
    FAST NEWS: Simcere’s revenue jumps on rising innovative drug sales
    2096.HK
  2. CStone breaks up with drugs partner as U.S. rollout stalls
    2616.HK
  3. AstraZeneca pays hefty price for Chinese weight-loss drug
    AZN.US
  4. FAST NEWS: Simcere gets exclusive rights to innovative influenza drug
    2096.HK
  5. BeiGene goes for global growth with sales and R&D push
    BGNE.US 6160.HK
  6. Everest reaches new heights on growing drug sales
    1952.HK
  7. InSilico seeks IPO boost to get AI drugs over the line
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo File-alt

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners